Jefferies Comments On Atara Biotherapeutics (Shares Up 20% Fri.) In Mid-Day Note, Says 'Overhang Removed With Start of Phase III Trials...Full Speed Ahead'; Maintains Buy Rating, $30 Price Target
Paul Quintaro